Review Article
Review of Preclinical and Clinical Studies of Bone Marrow-Derived Cell Therapies for Intracerebral Hemorrhage
Table 3
Ongoing trials registered in clinicaltrials.gov.
| | Trial identifier/country | Cell type | Route | Study design | Type of stroke | Age range | Time from onset to transplantation | Number of stroke patients to be included (controls) | Number of injected cells | Started | Status |
| | NCT02245698/India | Autologous BM-MNC | IT | Phase 1, nonrandomized, open-label | Ischemic or hemorrhagic stroke | 18–80 | Not specified | 200 (no controls) | Not specified | 12/2008 | Recruiting |
| | NCT01714167/China | Autologous BM-MSC | IC | Phase 1, nonrandomized, open-label | Ischemic or hemorrhagic stroke | 40–70 | 3–60 months | 30 (controls not specified) | 2 × 106 to 4 × 106 | 06/2012 | Recruiting |
| | NCT01832428/India | Autologous BM-MNC | IT | Phase 1–2, nonrandomized, open-label | Ischemic or hemorrhagic stroke | 18–70 | Not specified | 50 (no controls) | 1 × 108 (3 doses with one-week interval) | 09/2014 | Recruiting |
|
|
IC: intracerebral; IT: intrathecal; BM-MNC: bone marrow mononuclear cells; BM-MSC: bone marrow-derived mesenchymal stem cells.
|
